Summary
Philip Morris International Inc. (PM) filed an 8-K on December 13, 2022, detailing key executive appointments and compensation adjustments. The most significant change is the appointment of Jorge Insuasty as the full-time President of Vectura Fertin Pharma, effective January 1, 2023. This move signifies a dedicated leadership focus for this important segment of the business, with Mr. Insuasty continuing to report directly to CEO Jacek Olczak and no change to his compensation. Additionally, the filing outlines compensation adjustments for Frederic de Wilde, who is transitioning to a broader regional leadership role covering South and Southeast Asia, CIS, the Middle East, and Africa. These adjustments include a promotion in salary grade, an increased base salary to CHF 1,000,008, and revised annual incentive and equity award targets. These organizational realignments underscore PM's ongoing strategic adjustments and focus on key growth areas.
Key Highlights
- 1Jorge Insuasty appointed full-time President, Vectura Fertin Pharma, effective January 1, 2023.
- 2Mr. Insuasty will no longer serve as Chief Life Sciences Officer; Badrul Chowdhury (Chief Life Sciences Officer, Smoke-Free Products) will report directly to the CEO.
- 3No changes to Mr. Insuasty's compensation arrangements associated with his new role.
- 4Frederic de Wilde appointed President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region.
- 5Mr. de Wilde's base salary increased to CHF 1,000,008 (approx. $1,080,009).
- 6Mr. de Wilde's annual incentive compensation target set at 125% of new base salary.
- 7Mr. de Wilde's equity award target set at 275% of new base salary.